<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161634">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151695</url>
  </required_header>
  <id_info>
    <org_study_id>mEdICARE</org_study_id>
    <nct_id>NCT02151695</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.</brief_title>
  <official_title>Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <authority>France: ANSM - French Health Products Safety Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proliferative diabetic retinopathy is a serious complication of diabetes mellitus, partly
      consecutive to upregulation of vascular endothelial growth factor (VEGF) as a consequence of
      retinal ischemia leads. Aflibercept has been approved by FDA and European medicine agency
      for treatment of exudative age-related macular degeneration, another retinal disease
      characterized by choroidal new vessels.

      The aim of this pilot study is to evaluate the efficacy and the safety of Aflibercept
      intravitreal injections compared to panretinal photocoagulation for proliferative diabetic
      retinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Percentage of patients with regression of retinal neovascularization between baseline and 12th month.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Naive Patients With Uncomplicated PDR.</condition>
  <arm_group>
    <arm_group_label>Panretinal photocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept intravitreal injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>panretinal photocoagulation</intervention_name>
    <arm_group_label>Panretinal photocoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept intravitreal injections</intervention_name>
    <arm_group_label>Aflibercept intravitreal injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diabetes mellitus type 1 or type 2 complicated by PDR

          -  Male or female over 18 years

          -  HbA1c &lt;11% at study entry

          -  Systolic blood pressure &lt;160 mmHg and diastolic blood pressure &lt;105 mmHg at study
             entry

          -  Backgrounds clear eye, pupil dilation and patient cooperation sufficient to allow
             examination or fundus photographs of good quality

        Exclusion Criteria:

          -  Hypersensitivity to aflibercept or to any of the excipients

          -  History of retinal laser (macular or panretinal photocoagulation), of intravitreal
             injections, of vitrectomy in the eye studied

          -  PDR associated with tractional retinal detachment in the eye studied

          -  PDR associated with fibrovascular proliferation in the eye studied

          -  Florid diabetic retinopathy

          -  Eye infection or periocular active or suspected

          -  Unbalanced glaucoma in the eye studied

          -  Other eye disease in the eye studied

          -  Patients with significant medical problems that may interfere with the evaluation of
             the safety or efficacy of the treatment studied
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
    <phone>+33 (0)5.49.44.44.44</phone>
    <email>nicolas.leveziel@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
